Skip to main content

Table 1 INCREASE study eligibility criteria

From: INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol

Inclusion criteria Exclusion criteria
1. Age ≥ 65 years 1. Allergy or known intolerance to scopolamine patches
2. Non-demented 2. Narrow-angle glaucoma
3. No previous reaction or contraindication to scopolamine patch, or medical condition warranting dose adjustment in scopolamine patch including but not limited to: open angle glaucoma, gastrointestinal or urinary outlet obstructions, seizures, or psychosis 3. Difficulty swallowing
4. No contraindications to Aβ PET scan including hypersensitivity to PET ligand (florbetapir) or radiation exposure in the past year that would exceed acceptable safe annual exposure in combination with the Aβ PET 4. Stomach or bowel problems (e.g., blockage, muscle weakness, ulcerative colitis)
5. Medically stable and able to complete all study activities, in the opinion of the investigator 5. Myasthenia gravis
6. Reporting at least one potentially inappropriate medication as listed in the Beers 2015 criteria 6. Blockage of the urinary tract
7. Living in the community 7. Seizures
8. Able to identify a study partner who will drive the participant to and from the scopolamine-challenged visits 8. Psychosis
9. Willing to participate in this intervention study 9. Contraindications to Aβ PET scan including hypersensitivity to PET ligand (florbetapir) or radiation exposure in the past year that would exceed acceptable safe annual exposure in combination with the amyloid β PET
  1. PET positron emission tomography,  amyloid beta